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INTRODUCTION
Tuberous Sclerosis Complex (TSC) is
an autosomal dominant syndrome with
95% penetrance, and a birth incidence of
1 in 11,000 (1). It is characterized by the
multi-organ development of benign and
occasionally malignant tumors that most
frequently affect the central nervous sys-
tem, abdomen, and skin (2). In particular,
the kidney tumors include angiomy-
olipomas and renal cell carcinomas. An-
giomyolipomas consist of smooth muscle
cells, adipose tissue, and disorganized
thick-walled vascular channels (3). Their
abnormal vasculature may lead to spon-
taneous life-threatening bleeding (4). An-
giomyolipomas increase in size and/or
number in about 60% of children affected
by TSC, highlighting the need for close
surveillance of the kidneys and the entire
abdomen (5). TSC can occur in associa-
tion with pulmonary lymphangioleiomy-
omatosis (LAM), a progressive and often
fatal interstitial lung disease character-
ized by the diffuse proliferation of abnor-
mal smooth muscle cells and cystic de-
generation of lung parenchyma. The
TSC2 smooth muscle cells in angiomyo-
lipomas are very similar to those of pul-
monary LAM, and genetic data suggest
that LAM may be the result of benign
cell metastases, a highly unusual disease
mechanism (6,7).
TSC is characterized by mutations in
the tumor suppressor genes TSC1 on
chromosome 9q34 or TSC2 on chromo-
some 16p13, which seem to act together
as a complex of the encoded hamartin
(TSC1) and tuberin (TSC2) proteins (8).
These mutations lead to similar clinical
phenotypes, which are more severe in the
case of the TSC2 subtype (9). The
TSC1/TSC2 complex negatively regulates
cell size and proliferation (10,11) is a di-
rect target of Akt, a PI3K-regulated effec-
tor that promotes cell growth and sur-
vival by means of a mammalian target of
rapamycin (mTOR)-dependent mecha-
nism (12). Most of the extracellular and
intracellular signaling pathways involved
in the regulation of growth factor- and
nutrient-mediated cell growth are inte-
grated by mTOR (13). Rapamycin is a mi-
crobial product that counteracts these ef-
fects by inhibiting mTOR, and Akt is a
pro-survival and pro-oncogenic protein
that is phosphorylated following the acti-
vation of growth factor receptors (13).
Akt phosphorylation decreases the ability
of TSC2 to inhibit the phosphorylation of
the mTOR substrates S6 kinase and eu-
karyotic initiation factor 4E binding pro-
tein-1 (13-15), and excessive Akt, mTOR,
Survivin Expression in Tuberous Sclerosis Complex Cells
Address correspondence and reprint requests to Alfredo Gorio, Department of Medicine,
Surgery and Dentistry, School of Medicine, University of Milan, Polo San Paolo, Via A. Di
Rudinì 8, 20142 Milano, Italy. Phone: + 39 0250323032; Fax: + 39 0250323033; E-mail: 
alfredo.gorio@unimi.it
Submitted October 25, 2006; Accepted for publication January 4, 2007.
Stephana Carelli,1,3 Elena Lesma,1 Simona Paratore,1,3 Vera Grande,1 Giorgia Zadra,1 Silvano Bosari,2
Anna Maria Di Giulio,1 and Alfredo Gorio1,3
1Laboratory of Pharmacology, Dept. of Medicine, Surgery and Dentistry, University of Milan, Polo H. San Paolo,  Milano, Italy;
2Pathology Unit, Dept. of Medicine, Surgery and Dentistry, University of Milan, Polo H. San Paolo,  Milano, Italy; 3Clinical Pharma-
cology, IRCCS Humanitas, Rozzano, Milano, Italy
Tuberous Sclerosis Complex (TSC) is a tumor suppressor gene disorder with mutations of TSC1/TSC2 genes. This leads to the de-
velopment of hamartomas that most frequently affect central nervous system, kidney, and skin. Angiomyolipomas are abdomi-
nal masses made up of muscle vessels and adipose tissues that grow mostly in proximity to kidneys and liver. Bleeding and kid-
ney failure are the major justification for surgery. This study shows that angiomyolipoma-derived human smooth muscle TSC2–/–
cells express the apoptosis inhibitor protein survivin when exposed to IGF-1. Survivin expression is also triggered whenever culture
conditions perturb normal TSC2–/– cell function, such as the omission of EGF from the growth medium, the supplementation of anti-
EGFR, blockade of PI3K and ERK, or inhibition of mTOR. Interestingly, single or simultaneous inhibition of PI3K by LY294002 and ERK
by PD98059 does not prevent IGF-1-mediated survivin expression. Apoptogenic Smac/DIABLO, which is constitutively expressed
by TSC2–/– A+ cells, is down-regulated by IGF-1 even in the presence of LY294002 and PD98059. These cells release IGF-1 by means
of a negative feedback-regulated mechanism that is overrun when they are exposed to antibodies to IGF-1R, which increases
the released amount by more than 400%. The autocrine release of IGF-1 may therefore be a powerful mechanism of survival of
the tightly packed cells in the thick-walled vessels of TSC angiomyolipoma and in lymphangioleiomyomatosis (LAM) nodules. Fu-
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and S6K activation causes various types
of tumor, including hamartomas (2).
The inhibitors of apoptosis (IAP) gene
family (16) is one of the most pursued
targets among the regulators of apopto-
sis. Survivin is a structurally unique IAP
protein (17) that is organized as a stable
dimer (18) and contains a single bac-
ulovirus IAP repeat (BIR) and a COOH
terminus coiled-coil domain (19). It has
been suggested recently that survivin has
dual function, as it is involved in both
mitosis and apoptosis (20,21). Survivin
expression is transcriptionally controlled
in a cell cycle-dependent manner, trig-
gered in the G2/M phase, and localized
near the microtubules of centrosomes
and mitotic spindle (22), and its down-
regulation leads to multiple cell division
defects with supernumerary centro-
somes, multipolar mitotic spindles, and
multinucleation (23-25).
Survivin also is involved in the sup-
pression of cell death triggered by extrin-
sic or intrinsic apoptotic stimuli (26,27).
When survivin expression is enhanced
by genetic manipulation in transgenic
mice, phenotypes consistent with its cy-
toprotective activity and enhanced cell
viability are observed (28), whereas inter-
ference with its expression/function by
means of antisense oligonucleotides,
dominant negative mutants, ribozymes,
or siRNA oligonucleotides triggers cas-
pase-dependent apoptosis and increases
apoptotic stimuli (24,29-32). Its anti-
apoptotic mechanism of action is not
completely understood, but it has been
suggested recently that it may affect the
upstream initiation of mitochondrial-me-
diated apoptosis (33). Furthermore, its
phosphorylation at threonine 34 allows
the formation of a complex with caspase-
9 and thus leads to the inhibition of
apoptosis (34). In addition to preventing
caspase-9 activation within a functional
apoptosome (35), survivin binds the
apoptogenic Smac/DIABLO released by
mitochondrial membranes (36).
One of the most significant features of
survivin is its expression in cancers and
embryonic and fetal tissues (37), whereas
its expression is very low or undetectable
in normal differentiated tissues (38). Sur-
vivin up-regulation occurs in response to
growth factor signaling (39,40), STAT ac-
tivation (41), oncogene activation (42),
loss of p53 (43,44), and PI3 kinase/Akt
signaling (45).
We have isolated and characterized two
cell populations from an angiomyolipoma
in a patient affected by TSC2: one consists
of  actin-positive TSC2 LOH smooth
muscle-like cells (A+) and the other of ker-
atin 8/18 positive TSC2 non-LOH epithe-
lial-like cells (R+). Both cell types are
HMB45 positive and require EGF for
growth and proliferation (46). We report
here that an angiomyolipoma in a TSC2
patient includes a small population of
survivin- expressing cells, and that the
same expression is also present in puri-
fied TSC2+/– epithelioid cells (R+). Sur-
vivin is not detectable in TSC2–/– smooth
muscle-like cells (A+), but the addition of
IGF-1 or removal of EGF from the growth
medium, or the exposure of A+ cells to
specific EGFR antibodies (Merck Bio-
sciences, Darmstadt, Germany), promote
survivin expression. A+ cells release
IGF-1, and agents such as anti-EGFR anti-
bodies increase IGF-1 release by up to
about 13 ng/1.5  105 cells/24 h.
MATERIALS AND METHODS
Materials
The SDS-PAGE materials came from
Biorad (Hercules, CA, USA); LY294002,
PD98059, rapamycin, staurosporine-A,
wortmannin, cycloheximide (CHX), and
recombinant human EGF (rhuEGF) came
from Sigma-Aldrich (St. Louis, MO,
USA); the fetal bovine serum and media
were purchased from Euroclone (Paign-
ton, UK); recombinant human IGF-1
(rhuIGF-1) was provided by Peprotech
EC Ltd.; the polyclonal antibodies against
survivin (FL-142), caspase-3 (H-277),
RhoA, and -actin came from Santa-Cruz
Biotechnology (Santa-Cruz, CA, USA);
the polyclonal antibody against -actin
came from Sigma-Aldrich, that against
keratin 8/18 from Neomarkers
(Freemont, CA, USA), and those against
Smac/DIABLO and phospho-S6 from
Cell Signaling (Beverly, MA, USA); the
mouse monoclonal antibody against
EGFR came from Merck Biosciences
(Darmstadt, Germany), and that against
IGF-1R from Calbiochem (Darmstadt,
Germany). All of the other reagents were
of high analytical grade and were pur-
chased from Sigma-Aldrich.
Cell Cultures
The primary cultures were isolated
from the angiomyolipoma of a 42-year-
old female TSC2 patient previously de-
scribed by Lesma et al. (46). The study
was approved by the Institutional Re-
view Board of Milan’s San Paolo Hospi-
tal. The  actin-positive TSC2 LOH
smooth muscle-like cells (A+) and keratin
8/18 positive TSC2 non-LOH epithelial-
like cells (R+) were kept in culture
medium containing a 50/50 mixture
of DMEM/Ham F12, supplemented
with hydrocortisone 2  10–7 mol/L,
rhuEGF 10 ng/mL, sodium selenite 5 
10–8 mol/L (Sigma), insulin 25 g/mL
(Sigma), transferrin 10 g/mL (Sigma),
ferrous sulfate 1.6  10–6 (Sigma), and
15% heat-inactivated fetal bovine serum
(FBS). C2C12 (mouse muscle myoblast)
cells, CT/G vascular smooth muscle cells
from human aorta (VSMCs), and A549
(human lung adenocarcinoma) cells were
obtained from the American Type Cul-
ture Collection (ATCC, Rockville, MD,
USA) and maintained in accordance with
the manufacturer’s instructions: C2C12
in DMEM medium, A549 in RPMI 1640
medium, and VSMCs in F12 medium.
FBS was added to all of the media at a
concentration of 10%. All of the cell lines
were kept at 37°C in a humidified atmos-
phere (5% CO2: 95% air). The cell cul-
tures (except that of C2C12) were rou-
tinely sub-cultivated by means of
trypsinisation to maintain long-phase
growth. For the comparative studies of
survivin expression, the cells were sub-
confluently grown as previously
described.
Cell proliferation was evaluated in the
presence of various agents added to the
culture media by counting the cells in
Neubauer chamber.
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Western Blotting
At the end of the treatments, the cell
plates were placed on ice, the medium
was removed, and the cells were lyzed in
SDS-containing buffer (2% SDS, 0.1 M
sodium acetate, 0.5 mM EDTA, 1 mM
phenylmethylsulphonylfluoride, 1 mM
aprotinin, 1 mM leupeptin, 2 mM
sodium orthovanadate, 2 mM sodium
fluoride). Angiomyolipoma was homog-
enized under isotonic condition (25 mM
TrisHCl, PH 7.4, 250 mM sucrose, 1% Tri-
ton X-100, 1% NP-40, 5 mM EDTA, 1 mM
EGTA, 1 mM phenylmethylsulphonylflu-
oride, 1 mM aprotinin, 1 mM leupetin,
2 mM sodium orthovanadate, 2 mM
sodium fluoride) using an Ultra-Turrax
T25. The homogenates were centrifuged
at 1500g for 20 min at 4°C, and the super-
natant was collected and used for West-
ern blot analysis.
Protein concentrations were deter-
mined using the Lowry Ciocalteau
method with BSA as standard. Equal
amounts (75 g) of solubilized protein
were dissolved in Laemmli sample
buffer (Biorad, Hercules, CA, USA), sep-
arated by SDS-PAGE in reducing condi-
tions, and electroblotted onto nitrocellu-
lose membranes. The blots were blocked
in 5% non-fat dry milk, 0.05% Tween-20
in TBS, pH 7.5, and probed with specific
antibodies overnight at 4°C. The mem-
branes were probed with horseradish
peroxidase-conjugated goat anti-rabbit
antibody (1:10,000) (Chemicon, Temec-
ula, CA) at room temperature for 1 h.
The protein was visualized by means of
the enhanced chemioluminescence detec-
tion system (ECL; Pierce, Rockford, IL,
USA), and the autoradiograms were ana-
lyzed using Kodak 1D 3.6 Software after
acquisition on a Kodak image station 440
CF (Kodak).
Immunocytochemistry
Paraffin-embedded tissue sections of
angiomyolipoma were stained with the
anti-survivin polyclonal antibody raised
against the full length of the protein
(Santa Cruz). Briefly, the slides were de-
waxed and rehydrated, treated with 3%
hydrogen peroxide in distilled water to
inhibit endogenous peroxidase activity
and, after extensive washing in TBS/Tri-
ton X-100, incubated overnight at 4°C
with a 1:200 dilution of the anti-survivin
antibody. Sections were then rinsed and
incubated with biotinylated goat anti-
rabbit antibody (Pierce), and visualized
using a standard ImmunoPure Ultrasen-
sitive ABC Detection Kit (Pierce) with
3,3-diaminobenzidine (DAB) as the
chromogenic substrate. Positive and neg-
ative controls were included.
The cells were seeded and maintained
in culture for 24 h before staining for sur-
vivin. Endogenous peroxidase activity
was blocked with 3% hydrogen peroxide
for 1 min at room temperature. Non-
specific background was eliminated by
incubating the cells with 1.5% BSA in
0.2% Triton X-110 in PBS for 90 min, after
which they were incubated overnight at
4°C in a humidified chamber with poly-
clonal antibody against survivin in 0.1%
BSA. They were then rinsed and incu-
bated with biotinylated goat anti-rabbit
antibody (Chemicon) for 90 min at room
temperature, and visualized using a
standard ImmunoPure Ultrasensitive
ABC Detection Kit (Pierce) with 3,3-
diaminobenzidine (DAB) as chromogen.
Cell Immunofluoroscence Microscopy
The cells were cultured on glass slides,
permeabilized with 70% methanol for
10 min, and dried in air, and the primary
antibodies against -actin (1:100; Sigma),
RhoA (1:100; Santa Cruz) and keratin
8/18 (1:100; Neomarkers) were applied
overnight at 4°C. The samples were incu-
bated for 3 h at room temperature with
fluorescein isothiocyanate-conjugated rab-
bit anti-mouse antibody (Chemicon) for
-actin and keratin 8/18, and fluorescein-
conjugated donkey anti-goat antibody
(Chemicon) for RhoA. After washing, the
slides were mounted in 50% glycerol with
1 g/mL 4,6-diamono-2-phenylindole.
IGF-1 Release Assay
The IGF-1 released in the culture
media was measured by means of an 
enzyme-linked immunosorbent assay
(ELISA) for human IGF-1 (Biosource 
International) according to the manufac-
turer’s instructions. Briefly, the cells were
seeded in 5 cm Petri dishes at a dilution
of 1.5  105 cells/mL and, before testing,
maintained in culture for different times
(1, 5, 14 or 21 days) or treated as stated
in the Results. Fresh media were col-
lected and immediately stored at –80°C.
Statistical Analyses
The data are expressed as mean val-
ues ± SEM, and were statistically ana-
lyzed using Student t-test or ANOVA
followed by Tukey’s test; significance is
indicated for P values of * < 0.05. All of
the analyses were made using GraphPad
Prism 4.0 software.
RESULTS
Survivin Expression in TSC2
Angiomyolipoma
Figure 1A (panel a) shows the three
typical cell components of angiomy-
olipoma (adipocytes, smooth muscle cells,
and vascular structures with thick muscu-
lar walls) in hematoxylin- and eosin-
stained sections of a specimen surgically
removed from a TSC2 patient. Survivin-
positive cells were most frequently
detected in the areas of the angiomyo-
lipoma in which smooth muscle cells
were rare (Figure 1A, panels b and c). A
detail is shown in Figure 1A, panel d.
The expression of survivin in human
angiomyolipoma was also assayed by
means of the Western blotting of four dif-
ferent samples (Figure 1B), with A549
cells being used as positive control (47).
As survivin clearly plays an anti-apop-
totic role (48), we also investigated cas-
pase-3 by means of an antibody recog-
nizing both the pro-peptide and the
active form, and found that it was abun-
dantly expressed in all of the angiomy-
olipoma samples (Figure 1B).
Survivin Expression in Isolated TSC2
Cells
Two pure homogeneous cell popula-
tions were isolated from the angiomy-
olipoma of a TSC2 patient and character-
ized by sub-cloning at limiting dilution
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(46). One population consisted of elon-
gated, flat cells highly positive for smooth
muscle-specific -actin (Figure 2a); the
cells also are labeled by anti-HMB45 anti-
body (46), a TSC marker (49,50), but are
negative for S100 and keratin 8/18. These
smooth muscle-like cells (A+) are LOH
(a mutation on chromosome 16p13.3 at
exon 18 consisting of an A/T substitution)
and do not express tuberin (46). Con-
versely, the epithelioid cells (R+) were
highly positive for keratin 8/18 and RhoA
(Figure 2b), and negative for -actin and
S100; they are not LOH and express tu-
berin in both its phosphorylated and non-
phosphorylated forms (46).
Hamartin is expressed quite abun-
dantly in both A+ and R+ cells (46). The
immunocytochemical localization of sur-
vivin clearly labeled R+ cells (Figure 3A,
panels b and b), but the A+ cells were
negative (Figure 3A, panels a, a). In par-
ticular, survivin was detected in both the
nuclear and extra-nuclear portions of R+
cells. Survivin also was expressed in the
control A549 cells (Figure 3A, panel c
and c). Western blotting confirmed the
absence of survivin expression in the
A+ cells, and its abundance in R+ cells
(Figure 3B).
Pharmacological Regulation of
Survivin Expression in Isolated TSC2
Cells
TSC2 is a direct substrate of Akt, a
PI3K target involved in regulating cell
growth and proliferation (13). Forty-eight
h exposure of A+, R+, and A549 cells to
mTOR-inhibiting rapamycin (100 ng/mL)
or PI3K-inhibiting LY294002 (LY, 100 M)
induced survivin expression in the A+
cells, and did not change it in the R+
and A549 cells (Figure 4A). Exposure to
staurosporine (1 M) for 48 h also trig-
gered survivin expression in the A+ cells
(data not shown). Caspase-3 levels were
not changed under these conditions
(Figure 4A). The induction of survivin
expression also was established morpho-
logically by means of immunocytochem-
istry (Figure 4B). Human aorta smooth
muscle cells (VSMCs) were used as con-
trols for the human smooth muscle TSC2
cells. Under physiological conditions, as
well as in the presence of rapamycin
(100 ng/mL), LY (100 M), wortmannin
(320 nM), and staurosporine (1 M),
survivin was undetectable in VSMCs
(Figure 4C); pro-caspase-3 was ex-
pressed, but none of the experimental
conditions affected its level of expression
(Figure 4C).
Apoptosis can be triggered by multiple
stimuli, including cytokines, free radi-
cals, toxins, and growth factor with-
drawal (51); furthermore, A+ and R+ cells
are routinely grown in the presence of
10 ng/mL EGF, and exposure to anti-
EGFR leads to their death (46). We grew
A+ and R+ cells for 48 h in standard
medium with and without EGF, or with
the addition of IGF-1 (50 ng/mL) in the
absence of EGF. The removal of EGF
from standard medium and exposure to
IGF-1 in the absence of EGF triggered the
expression of survivin in the A+ cells,
and the same experimental conditions
increased the expression of survivin in
R+ cells (Figure 5A, upper panel). Pro-
Figure 1. Survivin immunocytochemical localization in a TSC2 patient angiomyolipoma. 
A: Adjacent sections were stained with hematoxylin and eosin (a), and exposed to a
polyclonal antibody against survivin (b-d). Immunocytochemistry revealed survivin-
positive cells scattered in the parenchyma and localized in areas that were relatively
poor in smooth muscle cells; survivin was mainly localized in the cytoplasm (d, arrow).
B: Western blot evaluation of survivin expression in four different samples of angiomy-
olipoma. A549 cells were used as a positive control of survivin and caspase-3 expression.
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caspase-3 levels were apparently unaf-
fected in the A+ cells, and only slightly
increased in the R+ cells (Figure 5A,
lower panel).
The induction of survivin expression
in A+ cells also was triggered when IGF-1
was added to the standard culture
growth medium containing EGF (Figure
5B). IGF-1-mediated survivin expression
in A+ cells was accompanied by the
down-regulation of Smac/DIABLO. This
was not observed when IGF-1 was
added to the growth medium without
EGF, and the increased survivin level
was accompanied by the expression of
Smac/DIABLO (Figure 5B). The absence
of both growth factors led to the same
survivin and Smac/DIABLO results. It is
well known that survivin-mediated
apoptosis suppression may occur via a
direct interaction with the caspase activa-
tor Smac/DIABLO (36). None of the ex-
perimental conditions affected the ex-
pression of phospho-S6 and caspase-3.
The pharmacological induction of sur-
vivin in TSC2 cells was quite rapid and
did not require serum: it was expressed
as little as 2 h after the addition of IGF-1
or LY to serum-deprived standard
medium, and the inhibition of PI3K by
LY did not antagonize the effect of IGF-1
on survivin expression (Figure 5C).
Cell Proliferation and Survivin
Expression
Adding EGF to the culture medium al-
lows the proliferation of A+ cells (46)
and, as described above, keeps the ex-
pression of survivin at undetectable lev-
els. However, when these cells were ex-
posed for 48 h to EGFR antibodies
(5 g/mL) raised against the receptor
domain that interacts with the ligand
(clone 225), survivin expression was
greatly enhanced (Figure 6A). The induc-
tion mediated by the blockade of EGFR
was boosted by co-incubation with
IGF-1. The inhibition of MAPK by
PD98059 (PD, 30 M) and LY (100 M)
also increased the expression of survivin
in A+ cells (Figure 6A), which was en-
hanced further by the co-incubation of
IGF-1 with LY and PD, and even the si-
multaneous co-addition of PD (30 M)
and LY (100 M) did not prevent the
IGF-1 promotion of survivin expression
(data not shown). This evidence suggests
that IGF-1 may also act through a path-
way other than those regulated by
PI3K/Akt and MAPK. Smac/DIABLO
expression was down-regulated by
IGF-1, without counteracting the effects
of PI3K and MAPK blockade even when
the inhibitors were added simultane-
ously; conversely, the effects were en-
hanced by anti-EGFR (Figure 6A). When
exposure to anti-EGFR was extended
from 48 h to five days, the period in
which its killing action begins to take
place (46), survivin expression was sig-
nificantly reduced in the TSC2–/– A+ cells
(Figure 6B), and the same occurred when
rapamycin was administered for 5 days.
However, prolonged anti-EGFR or ra-
pamycin treatment did not affect
Smac/DIABLO expression (Figure 6B).
Only rapamycin and anti-EGFR af-
fected the proliferation rate during 48 h
exposure, which suggests that the in-
creased expression of survivin may be
unrelated to proliferation in this instance
(Figure 6C).
IGF-1 Release
We have reported previously that A+
cells are capable of releasing IGF-1 into
Figure 2. Two types of purified TSC2 cells. Exposure to an -actin antibody (a,b) specific
for smooth muscle cells showed that the antigen was present in flat, elongated TSC2–/–
cells (A+) but undetectable in epithelioid TSC2+/– cells (R+). Rho-A was very abundant in R+
cells (a,b), which were labeled with the anti-keratin 8/18 antibody (b). No anti-keratin
8/18 labeling was observed in A+ cells (a).
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culture medium (46), and the findings of
this study show that this release contin-
ues even when the period of culture is
extended to 21 days. During the early
stages, the A+ cells released smaller
amounts of IGF-1 (4.58 ng/1.5  105
cells/24 h after one, and 4.71 ng/
1.5  105 cells/24 h after 5 days), but this
markedly and highly significantly in-
creased to 9.14±0.21 ng/1.5  105
cells/24h and 14.21±0.65 ng/1.5  105
cells/24h after respectively 14 and 21
days (Figure 7A). This release was de-
pendent on protein synthesis (it was sig-
nificantly reduced by the addition of cy-
cloheximide 10 g/mL to the culture
medium) and was unrelated to cell pro-
liferation or mTOR activity as rapamycin
(5 ng/mL) had no effect (Figure 7B). In-
terestingly, blocking EGFR or IGF-1R by
means of their specific antibodies (clone
225 and IR3) greatly increased IGF-1 re-
lease (Figure 7C). Evaluation of the time-
course of IGF-1 release over 24 h showed
that it was quite constant during the 1st
10 h, and then sharply decreased (0-5 h:
0.912 ng/h/1.5  105 cells, 0-10 h:
Figure 3. Survivin expression in TSC2 cells. A: Hematoxylin and eosin staining of TSC2–/– A+ cells (a), TSC2+/– R+ cells (b), and A549 cells (c);
immunocytochemical staining revealed that the R+ (b) and A549 cells (c) were rich in survivin, whereas the A+ cells were negative (a).
B: Western blot analysis of survivin expression in A+, R+, and A549 cells (upper panel); as an internal control of gel loading, the membrane
also was decorated with -actin antibody (lower panel). Western blotting did not detect survivin in the TSC2–/– A+ cells, but showed its
abundance in TSC2+/– R+ and A549 cells.
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1.006 ng/h/1.5  105 cells, 0-24 h:
0.279 ng/h/1.5  105 cells). This may
have been due to the accumulation of
IGF-1 in the collection medium, which
may exert a negative feedback control on
the release mechanism. The more effec-
tive action of anti-IGF-1R may be due to
a blockade of this negative feedback
regulation.
DISCUSSION
The results of this study show that an-
giomyolipoma cells from a TSC2 patient
express the apoptosis inhibitor survivin.
Two pure homogenous cell populations
were isolated from the angiomyolipoma
and characterized: TSC2–/– A+ smooth
muscle cells and TSC2+/– R+ epithelioid
cells. The latter show detectable levels of
survivin, whereas the former express the
protein when the growth medium is sup-
plemented with IGF-1. Furthermore, sur-
vivin is expressed when the cells are ex-
posed to conditions that perturb normal
TSC2–/– cell function, such as the omis-
sion of EGF from the growth medium,
the addition of anti-EGFR, the blockade
of PI3K and ERK, or the inhibition of
mTOR.
Interestingly, single or dual inhibition
of PI3K by LY and ERK by PD does not
prevent the triggering of survivin expres-
sion in TSC2–/– A+ cell exposed to IGF-1,
therefore IGF-1 may play a role in the
survival of these cells via a pathway that
does not require PI3K and ERK function.
Such a role is also supported by the
IGF-1-mediated down-regulation of
apoptogenic Smac/DIABLO, which is
constitutively expressed by TSC2–/– A+
cells. Once again, the inhibition of PI3K
by LY and ERK by PD does not prevent
the marked reduction of Smac/DIABLO
expression caused by IGF-1 exposure but,
unlike that of survivin, its expression is
not affected by LY or PD applied alone.
We found that the amounts of IGF-1
released by TSC2–/– A+ cells into the cul-
ture medium become progressively
larger over time, being much higher on
day 21 than on day one or five. This is
probably an auto-regulated process with
a feedback mechanism activated by the
Figure 4. mTOR and PI3K inhibition promotes survivin expression in TSC2–/– cells. Twenty-four
h after plating, the cells were incubated with rapamycin (Rapa, 100 ng/mL) or LY294002
(LY, 10 M) for 48 h. A: Western blot detection of survivin and procaspase-3 expression.
Under control conditions, the TSC2–/– A+ cells did not express detectable levels of survivin,
which only became apparent after mTOR and PI3K blockade; procaspase-3 was ex-
pressed under all experimental conditions. The R+ and A549 cells show survivin and pro-
caspase-3 expression under all experimental conditions. B: Immunocytochemical detec-
tion of survivin. The A+ cells became positive to antibody labeling after exposure to
rapamycin and LY. C: Twenty-four h after plating in specific standard medium, VSMC cells
were treated with rapamycin (100 ng/mL), LY (100M), wortmannin (W, 320 nM) and stau-
rosporine (St, 1 M) for 48 h, and survivin and procaspase-3 expression was assessed by
means of Western blotting. The VSMCs showed the expression of procaspase-3, but not
survivin.
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accumulation of IGF-1 in the growth
medium because, during the first 10 h of
24 h collection, the amounts of IGF-1 re-
leased remained quite constant and were
larger than later. However, this feedback
regulation is overcome if TSC2–/– A+ cells
are exposed to antibodies to IGF-1R,
which increases the released amount by
more than 400%. We have reported pre-
viously that TSC2–/– A+ cells exposed to
anti-IGF-1R gradually die in 12-14 days
(46), and so the autocrine release of
IGF-1 seems to be a powerful survival
mechanism activated by TSC2–/– smooth
muscle cells which are tightly packed
in the thick-walled vessels of TSC angio-
myolipoma and lymphangioleiomyo-
matosis (LAM) nodules.
Survivin originally was isolated as a
member of IAP family, and it was sug-
gested that it plays a fundamental role in
inhibiting apoptosis and regulating the
mitotic process and cell proliferation
(19,20). Its expression profile is indicative
of this role as it is detectable in embry-
onic and fetal tissues, but poorly or not
expressed in normal adult tissues (37).
However, it is expressed in cancer cells,
and higher levels of expression have
been correlated with a poor prognosis
(38); its expression also has been corre-
lated with resistance to chemotherapeu-
tic agents, thus suggesting that lower ex-
pression may indicate greater tumor
sensitivity to chemotherapy (52,53). Sur-
vivin affects the initiation of mitochondr-
ial-mediated apoptosis by binding the
Smac/DIABLO released from mitochon-
dria membranes, and then inhibiting cas-
pase-9 activation (33-36).
Epithelioid TSC2+/– R+ cells constitu-
tively express survivin, but it is unde-
tectable in smooth muscle TSC2–/– A+
cells both in vivo and in vitro. However,
its expression increases dramatically
when the cells are exposed to agents that
affect their function, such as LY, PD, and
the mTOR inhibitor rapamycin. At a dose
of 5 ng/mL, rapamycin affects the prolif-
eration of smooth muscle TSC2–/– A+ cells
(46), but LY and PD do not; the addition
of anti-EGFR to the growth medium af-
fects the rate of proliferation and pro-
motes the expression of survivin. Both ra-
pamycin and anti-EGFR increase survivin
levels without affecting the constitutively
expressed Smac/DIABLO, but their effects
are time related: after five days’ treatment,
the survivin-promoting effects of anti-
EGFR or rapamycin have almost van-
ished, whereas Smac/DIABLO is still ex-
Figure 5. Modulation of survivin expression in TSC–/– A+ cells by IGF-1 and EGF. A,B: The
cells were cultured for 48 h in standard medium, or in the same medium devoid of EGF in
the presence or absence of IGF-1 (50 ng/mL). C: After 24 h in serum-deprived medium,
IGF-1 (50 ng/mL), LY294002 (LY, 100 M), or both were added to the serum-deprived
medium for 2 or 6 h, and survivin, Smac/DIABLO, caspase-3, and the phosphorylated
form of S6 were assessed by means of Western blotting. Removing EGF from the growth
medium (A), or adding IGF-1 in the presence or absence of EGF (B), triggered the expres-
sion of survivin. The expression of proapoptotic Smac/DIABLO in A+ cells was down-regu-
lated by IGF-1, but only in the presence of EGF (B). The omission of EGF counteracted the
suppressive action of IGF-1 on Smac/DIABLO expression (B). Serum-deprivation and LY, a
PI3K inhibitor, did not inhibit the rapid IGF-1 induction of survivin expression, which was al-
ready evident 2 h after drug exposure (C).
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Figure 6. Pharmacological regulation of survivin expression in TSC2–/– A+ cells. The cells were cultured for 48 h in standard medium, or
in the same medium in the presence of IGF-1 (50 ng/mL), LY294002 (LY, 100 M), PD98059 (PD, 30 M) or anti-EGF receptor antibody
(C225, 5 g/mL). A: Survivin expression was triggered by IGF-1 and all of the other agents. The action of IGF-1 was enhanced by the
co-administration of any of the other agents. The IGF-1-mediated attenuation of Smac/DIABLO expression was counteracted only by
anti-EGFR. B: Survivin and Smac/DIABLO expression evaluated by means of Western blotting after two and five days’ exposure to anti-
EGFR (C225, 5 g/mL) or rapamycin (Rapa, 5 ng/mL). OD quantification showed that the expression of survivin decreased over time,
whereas that of Smac/DIABLO did not. °°° P < 0.001 vs. two days of anti-EGFR treatment; *** P < 0.001 vs. two days of rapamycin treat-
ment. C: A total of 50  104 cells were plated and counted 48 h later in a modified Neubauer chamber. Rapamycin and anti-EGFR in-
hibited cell proliferation (the horizontal line represents cell number at plating); the other agents had no effect, and the rate of cell
growth was the same as under control condition. Despite their different effects on cell proliferation (white bars), all of the treatments
enhanced survivin expression (black bar).
R E S E A R C H  A R T I C L E
M O L  M E D  1 3 ( 3 - 4 ) 1 6 6 - 1 7 7 ,  M A R C H - A P R I L  2 0 0 7  |  C A R E L L I  E T  A L .  |  1 7 5
pressed at normal levels. We have re-
ported previously that anti-EGFR-in-
duced TSC2–/– A+ cell death begins after
five and seven days’ exposure, and so it
is possible that the progressive down-
regulation of survivin may be one of the
mechanisms triggered by anti-EGFR in
killing these cells. In addition, anti-EGFR
is probably a highly unfavorable signal
for cells that require EGF to grow and
proliferate (46): the 24-hour application
of anti-EGFR enhances the autocrine re-
lease of IGF-1, which is comparable to
that observed when the IGF-1 receptor is
blocked by means of the specific
antibody.
Epithelioid TSC2+/– R+ cells are very
sensitive to EGF and its omission from
the culture medium leads to a quick
death, whereas smooth muscle TSC2–/–
A+ cells stop proliferating but do not die
when EGF is not added (46). Further-
more, R+ cells secrete significantly
smaller amounts of IGF-1, about 10% of
that released by A+ cells (data not
shown). Both TSC2 cell types are there-
fore sensitive to EGF, but the extent of
their dependence is rather different and
R+ cells have a less developed ability to
release IGF-1. Smooth muscle TSC2–/– A+
cells have developed a survival strategy
that links the self-secretion of IGF-1 to
the expression of anti-apoptotic survivin
and the down-regulation of Smac/DIA-
BLO. This survival mechanism seems to
be quite specific as TSC2–/– A+ cells also
show the constitutive expression of p53,
which is genetically normal and without
any mutation (unpublished data), and re-
mains unaffected by IGF-1 or anti-EGFR
exposure, and more generally by all of
the experimental procedures used in this
study (unpublished data).
Furthermore, IGF-1 supplementation
promotes the proliferation of VSMCs and
inhibits that of A+ cells. The role of IGF-1
has thus changed from inducing prolifer-
ation in normal smooth muscle to auto-
secreted survival activity with no prolif-
erative ability in smooth muscle TSC2–/–
A+ cells (46).
The mechanisms developed by TSC2–/–
A+ cells in terms of IGF-1 action and sur-
Figure 7. TSC–/–A+ cells release IGF-1 in culture medium. The medium was removed and
the cells washed once, and then fresh medium was added and collected 24 h later for
IGF-1 assay. The collected media were immediately stored at –80°C until IGF-1 determi-
nation by ELISA. IGF-1 release is shown as a percentage of controls (fixed at 100%). A: The
cells were cultured for the indicated times (days) in standard medium. IGF-1 release was
quite constant during the first week in culture, and then progressively increased to peak
levels. B: The cells were grown for five days, and incubated for 24 h with fresh medium
(control, C) with and without the presence of cycloheximide (CHX, 10 g/mL) or ra-
pamycin (Rapa, 5 ng/mL). CHX greatly reduced IGF-1 release, whereas rapamycin did
not change it. C: The cells were grown for five days in standard medium (control, C) with
and without the presence of anti-EGFR (clone 225, 5 g/mL) or anti-IGF-1R antibody
(IR3, 5 g/mL). Both antibodies greatly enhanced IGF-1 release, but anti-IGF-1R was sig-
nificantly more effective than anti-EGFR. Mean values ± SEM; between-group differences
evaluated by ANOVA test: *** P < 0.001 vs control; °°° P < 0.001 vs 5 days; § P < 0.05 vs 14
days; € P < 0.05 vs anti-EGFR treatment.
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vivin expression are thus rather different
from those described in cancer, in which
the inhibition of PI3K leads to the down-
regulation of survivin expression and in-
creased sensitivity to chemotherapy (54-
57), and CD34+ cells, in which the
selective inhibition of PI3K and MAPK
blocks the up-regulation of survivin by
growth factors (58).
In conclusion, Tuberous Sclerosis
Complex (TSC) is a tumor suppressor
gene disorder characterized by muta-
tions in the TSC1 or TSC2 genes that
lead to the development of benign tu-
mors involving smooth muscle cells, and
also cause life-threatening LAMs. TSC2
is the form most often correlated with a
poor clinical outcome. We have isolated
and grown in vitro a pure colony of
TSC2–/– smooth muscle cells from an-
giomyolipoma (christened A+) that re-
quire EGF to grow, and die in 12-14 days
after exposure to EGFR and IGF-1R anti-
bodies (46). These cells secrete much
IGF-1 that is greatly increased when
they are subjected to killing insults, such
as exposure to EGFR and IGF-1R anti-
bodies. Pharmacological treatments ca-
pable of interfering with the function of
key enzymes such as PI3K, ERK, and
mTOR, or with vital EGFR functions,
such as the omission of EGF from
growth medium or exposure to anti-
EGFR, trigger the expression of survivin
by TSC2–/– smooth muscle cells. The au-
tocrine release of IGF-1 seems to be a
powerful survival mechanism activated
by TSC2–/– smooth muscle cells, which
are tightly packed in the thick-walled
vessels of TSC angiomyolipomas and
LAM nodules, and in which IGF-1 con-
centrations may increase to reach effec-
tive anti-apoptotic concentrations.
Future experimental therapies for TSC
and LAM will need to overcome this ob-
stacle to achieve their goal, and a novel
approach may be the targeted inhibition
of survivin, which may enhance sensitiv-
ity to TSC2 therapy.
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